Study to Assess Change in Quality of Life of Risankizumab Treatment in Adult Participants With Moderate-to-Severe Plaque Psoriasis
Plaque PsoriasisPsoriasis is a chronic, systemic, inflammatory disease in which skin cells build up and develop thick, red and white scaly patches on the skin. This study will assess the change in quality of life of risankizumab treatment in adult participants with moderate to severe plaque psoriasis real-world clinical practice.
Risankizumab is an approved drug for treating participants with Psoriasis. Approximately 700 participants who are prescribed risankizumab by their physician in accordance with local label will be enrolled in approximately 70 sites worldwide.
Participants will receive risankizumab as prescribed by their physician according to their routine clinical practice and local label. Participants will be followed for up to 2.5 years.
There is expected to be no additional burden for participants in this trial. Participants will attend regular visits during the study at a hospital or clinic according to their routine clinical practice.
null
Participation Requirements
-
Sex:
ALL -
Eligible Ages:
18 and up
Participation Criteria
Inclusion Criteria:
* Participants with a Confirmed diagnosis of moderate-to-severe plaque psoriasis with or without joint involvement according to the treating physician's clinical judgment, prior to time of enrollment.
* Treatment with risankizumab is indicated per summary of product characteristics (SmPC) or local label and local prescribing/treatment guidelines.
* Decision to treat with risankizumab is made prior to and independently of study participation.
Exclusion Criteria:
* History of a sleep disorder diagnosis which the patient is currently being treated for.
* Current or recent (within the last 30 days) participation in an interventional clinical trial or an observational study.
* Currently receiving other biologic treatments and/or small molecules including Janus kinase (JAK) inhibitors, tyrosine kinase 2 (TYK2) inhibitors, and phosphodiesterase 4 (PDE4) inhibitors for any reason.
Study Location
Winnipeg Clinic /ID# 276751
Winnipeg Clinic /ID# 276751Winnipeg, Manitoba
Canada
Contact Study Team
Dermatrials Research /ID# 276714
Dermatrials Research /ID# 276714Hamilton, Ontario
Canada
Contact Study Team
JRB Research inc. /ID# 277730
JRB Research inc. /ID# 277730Ottawa, Ontario
Canada
Contact Study Team
North York Research Inc /ID# 276835
North York Research Inc /ID# 276835Toronto, Ontario
Canada
Contact Study Team
Lynderm Research Inc /ID# 276755
Lynderm Research Inc /ID# 276755Markham, Ontario
Canada
Contact Study Team
Cca Medical Research /ID# 276944
Cca Medical Research /ID# 276944Ajax, Ontario
Canada
Contact Study Team
SKiN Centre for Dermatology /ID# 277594
SKiN Centre for Dermatology /ID# 277594Peterborough, Ontario
Canada
Contact Study Team
Dre Angelique Gagne-Henley M.D. inc. /ID# 276687
Dre Angelique Gagne-Henley M.D. inc. /ID# 276687Saint-Jérôme, Quebec
Canada
Contact Study Team
Quinte dermatology /ID# 277497
Quinte dermatology /ID# 277497Belleville, Ontario
Canada
Contact Study Team
Rejuvenation Dermatology Clinic Oakville /ID# 277492
Rejuvenation Dermatology Clinic Oakville /ID# 277492Oakville, Ontario
Canada
Contact Study Team
Eternal Springtime Dermatology /ID# 278598
Eternal Springtime Dermatology /ID# 278598Thunder Bay, Ontario
Canada
Contact Study Team
Wiseman Dermatology Research /ID# 276847
Wiseman Dermatology Research /ID# 276847Winnipeg, Manitoba
Canada
Contact Study Team
Factor Dermatology /ID# 278610
Factor Dermatology /ID# 278610Ottawa, Ontario
Canada
Contact Study Team
Lovegrove Dermatology /ID# 276797
Lovegrove Dermatology /ID# 276797London, Ontario
Canada
Contact Study Team
Centre for Medical and Surgical Dermatology /ID# 278775
Centre for Medical and Surgical Dermatology /ID# 278775Whitby, Ontario
Canada
Contact Study Team
- Study Sponsored By
- AbbVie
- Participants Required
- More Information
- Study ID:
NCT07039110